Avinger (AVGR) 10-K 6 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Mar. 02, 2020	Jun. 28, 2019
Document Information [Line Items]
Entity Registrant Name	Avinger Inc
Entity Central Index Key	0001506928
Trading Symbol	avgr
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		16,813,398
Entity Public Float			$ 19.4
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.001 per share

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 10,943,000	$ 16,410,000
Accounts receivable, net of allowance for doubtful accounts of $19 and $260 at December 31, 2019 and 2018, respectively	1,458,000	1,154,000
Inventories	3,912,000	3,422,000
Prepaid expenses and other current assets	311,000	635,000
Total current assets	16,624,000	21,621,000
Right of use asset	4,856,000
Property and equipment, net	1,661,000	2,078,000
Other assets	684,000
Total assets	23,825,000	23,699,000
Current liabilities:
Accounts payable	663,000	1,148,000
Accrued compensation	1,782,000	1,197,000
Series A preferred stock dividends payable		2,918,000
Accrued expenses and other current liabilities	654,000	1,449,000
Leasehold liability, current portion	722,000
Borrowings	8,967,000	7,486,000
Total current liabilities	12,788,000	14,198,000
Leasehold liability, long-term portion	4,135,000
Other long-term liabilities	7,000	41,000
Total liabilities	16,930,000	14,239,000
Commitments and contingencies (Note 8)
Stockholders’ equity:
Convertible preferred stock issuable in series, par value of $0.001 Shares authorized: 5,000,000 at December 31, 2019 and 2018 Shares issued and outstanding: 48,503 and 45,671 at December 31, 2019 and 2018, respectively; aggregate liquidation preference related to Series A convertible preferred stock of $48,325 and $44,718 at December 31, 2019 and 2018, respectively
Common stock, par value of $0.001 Shares authorized: 100,000,000 at December 31, 2019 and 2018 Shares issued and outstanding: 10,364,663 and 3,492,200 at December 31, 2019 and 2018, respectively	10,000	3,000
Additional paid-in capital	355,220,000	338,342,000
Accumulated deficit	(348,335,000)	(328,885,000)
Total stockholders’ equity	6,895,000	9,460,000
Total liabilities and stockholders’ equity	$ 23,825,000	$ 23,699,000

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Allowance for doubtful accounts	$ 19	$ 260
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	48,503	45,671
Preferred stock, shares outstanding (in shares)	48,503	45,671
Preferred stock, liquidation value	$ 48,325	$ 44,718
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	10,364,663	3,492,200
Common stock, shares outstanding (in shares)	10,364,663	3,492,200

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 9,131	$ 7,915
Cost of revenues	6,264	6,531
Gross profit	2,867	1,384
Operating expenses:
Research and development	5,692	6,009
Selling, general and administrative	16,534	18,404
Total operating expenses	22,226	24,413
Loss from operations	(19,359)	(23,029)
Interest income	288	214
Interest expense	(1,480)	(5,692)
Other income, net	1,101	949
Net loss and comprehensive loss	(19,450)	(27,558)
Accretion of preferred stock dividends	(3,580)	(2,918)
Deemed dividend arising from beneficial conversion feature of convertible preferred stock		(5,216)
Net loss applicable to common stockholders	$ (23,030)	$ (35,692)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (3.18)	$ (33.42)
Weighted average common shares used to compute net loss per share, basic and diluted (in shares)	7,239	1,068

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	July Public Offering [Member]Preferred Stock [Member]	July Public Offering [Member]Common Stock [Member]	July Public Offering [Member]Additional Paid-in Capital [Member]	July Public Offering [Member]Retained Earnings [Member]	July Public Offering [Member]	August Public Offering [Member]Preferred Stock [Member]	August Public Offering [Member]Common Stock [Member]	August Public Offering [Member]Additional Paid-in Capital [Member]	August Public Offering [Member]Retained Earnings [Member]	August Public Offering [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Common Stock [Member]	Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Series B Preferred Stock [Member]Retained Earnings [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]Preferred Stock [Member]	Series C Preferred Stock [Member]Common Stock [Member]	Series C Preferred Stock [Member]Additional Paid-in Capital [Member]	Series C Preferred Stock [Member]Retained Earnings [Member]	Series C Preferred Stock [Member]	Conversion of Series B Preferred Stock into Common Stock [Member]Preferred Stock [Member]	Conversion of Series B Preferred Stock into Common Stock [Member]Common Stock [Member]	Conversion of Series B Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series B Preferred Stock into Common Stock [Member]Retained Earnings [Member]	Conversion of Series B Preferred Stock into Common Stock [Member]	Conversion of Series C Preferred Stock into Common Stock [Member]Preferred Stock [Member]	Conversion of Series C Preferred Stock into Common Stock [Member]Common Stock [Member]	Conversion of Series C Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series C Preferred Stock into Common Stock [Member]Retained Earnings [Member]	Conversion of Series C Preferred Stock into Common Stock [Member]	Conversion of CRG into Series A Preferred Stock [Member]Preferred Stock [Member]	Conversion of CRG into Series A Preferred Stock [Member]Common Stock [Member]	Conversion of CRG into Series A Preferred Stock [Member]Additional Paid-in Capital [Member]	Conversion of CRG into Series A Preferred Stock [Member]Retained Earnings [Member]	Conversion of CRG into Series A Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017																																					83,359
Balance at Dec. 31, 2017																																					$ 1	$ 265,636	$ (301,327)	$ (35,690)
Issuance of common stock under officers’ and directors’ purchase plan (in shares)																																					4,401
Issuance of common stock under officers’ and directors’ purchase plan																																						21		21
Employee stock-based compensation																																						3,080		3,080
Exercises of warrants for common stock (in shares)																																					29,050
Exercises of warrants for common stock																																						581		581
Common stock issued to a vendor (in shares)																																					8,000
Common stock issued to a vendor																																						106		106
Issuance of stock (in shares)		216,618									17,979					8,586	728,500
Issuance of stock			$ 3,026		$ 3,026								$ 15,525		$ 15,525			$ 10,179		$ 10,179
Conversion of convertible securities (in shares)																					(16,278)	813,914				(6,416)	1,604,000				41,800
Conversion of convertible securities																											$ 2	$ (2)					$ 42,794		$ 42,794
Issuance of common stock to Lincoln Park (in shares)																																					4,358
Issuance of common stock to Lincoln Park																																						314		314
Accretion of Series A preferred stock dividends																																						(2,918)		(2,918)
Net and comprehensive loss																																							(27,558)	(27,558)
Balance (in shares) at Dec. 31, 2018																																				45,671	3,492,200
Balance at Dec. 31, 2018																																					$ 3	338,342	(328,885)	9,460
Issuance of common stock under officers’ and directors’ purchase plan (in shares)																																					36,087
Issuance of common stock under officers’ and directors’ purchase plan																																						72		72
Employee stock-based compensation																																						2,091		2,091
Exercises of warrants for common stock (in shares)																																					1,998,079
Exercises of warrants for common stock																																					$ 2	7,991		7,993
Issuance of stock (in shares)							3,813,559
Issuance of stock							$ 4	$ 3,807		$ 3,811
Conversion of convertible securities (in shares)																					(1,523)	380,750				(2,170)	542,500
Conversion of convertible securities																											$ 1	$ (1)
Accretion of Series A preferred stock dividends																																						(3,580)		(3,580)
Net and comprehensive loss																																							(19,450)	(19,450)
Issuance of common stock upon vesting of restricted stock units (in shares)																																					101,488
Issuance of common stock upon vesting of restricted stock units
Issuance of Series A preferred stock to pay dividends (in shares)																																				6,525
Issuance of Series A preferred stock to pay dividends																																						6,498		6,498
Balance (in shares) at Dec. 31, 2019																																				48,503	10,364,663
Balance at Dec. 31, 2019																																					$ 10	$ 355,220	$ (348,335)	$ 6,895

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (19,450)	$ (27,558)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	890	1,281
Amortization of debt issuance costs and debt discount	171	117
Stock-based compensation	2,091	3,080
Noncash interest expense and other charges	1,575	5,634
Common stock issued for services		106
Provision for excess and obsolete inventories	272	914
Other non-cash charges	(51)	126
Changes in operating assets and liabilities:
Accounts receivable	(248)	(160)
Inventories	(1,169)	(92)
Prepaid expenses and other current assets	128	5
Other assets	658	340
Accounts payable	(485)	(125)
Accrued compensation	585	334
Leasehold liability	(1,402)
Accrued expenses and other current liabilities	(795)	(2,208)
Other long-term liabilities	(34)	(260)
Net cash used in operating activities	(17,264)	(18,466)
Cash flows from investing activities
Purchase of property and equipment	(88)	(32)
Proceeds from sale of property and equipment	18	28
Net cash used in investing activities	(70)	(4)
Cash flows from financing activities
Proceeds from the issuance of convertible preferred stock, net of issuance costs		15,525
Proceeds from issuance of common stock and convertible preferred stock, net of issuance costs		10,179
Proceeds from issuance of common stock under officers’ and directors’ purchase plan	63	21
Proceeds from public offerings, net of issuance costs		3,026
Proceeds from exercise of common stock warrants	7,993	581
Debt discount in connection with loan amendment		(155)
Proceeds from the issuance of common stock	3,811	314
Net cash provided by financing activities	11,867	29,491
Net change in cash and cash equivalents	(5,467)	11,021
Cash and cash equivalents, beginning of period	16,410	5,389
Cash and cash equivalents, end of period	10,943	16,410
Supplemental disclosure of cash flow information
Cash paid for interest		60
Noncash investing and financing activities:
Conversion of CRG loan principal and accrued interest into Series A Convertible preferred stock		42,794
Issuance of Series A preferred stock as dividend payment	6,498
Disposal of fully depreciated property and equipment	54	2,849
Accretion of Series A Convertible preferred stock dividends	3,580	2,918
Reclassification of right of use asset to prepaid rent	462
Increase to right of use asset and leasehold liability arising from lease amendment	4,680
Transfer between inventory and property and equipment	$ 408	$ 51

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	1. Organization, Nature of Business Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. “OCT”) March 2016, 510 May 2018, 510 April 2019, August 2019. Liquidity Matters The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014 15, Presentation of Financial Statements - Going Concern (Subtopic 205 40 one In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of December 31, 2019, $348.3 $10.9 December 31, 2019 third 2020. $3.7 January 2020 $3.8 August 2019 April May 2019 $8.0 $10.2 November 2018 $3.0 July 2018 $15.5 February 2018 twelve may The Company can provide no not twelve no may one not Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of borrowings at December 31, 2019 2018 not Public Offerings On February 16, 2018, 17,979 1,797,900 $15.5 $0.001 no no not one 1 seventh 50 one 2 seventh 60th 50 60 seven April 2019, 60 60 2 seventh 41,800 $38.0 $41.8 2,090,000 On July 12, 2018, 216,618 $16.425 one two 108,309 July 16, 2018, $3.0 $15.80 July 16, 2021. On November 1, 2018, 728,500 8,586 $10.2 $0.001 no On August 26, 2019, 3,813,559 $1.18 $3.8 February 2018 $1.18 On January 31, 2020, 6,428,572 $0.70 $3.7 February 2018 $0.70

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	2. Basis of Presentation The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC (“SEC”). On January 30, 2018, 1 40 June 19, 2019 , 1 - 10 June 21, 2019. not Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may may Fair Value of Financial Instruments The Company has evaluated the estimated fair value of its financial instruments as of December 31, 2019 2018. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2019 2018, no December 31, 2019 2018. Concentration of Credit Risk, and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2019 2018. The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At December 31, 2019 2018, no 10% December 31, 2019 2018, no 10% The Company manufactures its commercial products in-house, including Pantheris and the Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations. The Company is subject to certain risks, including that its devices may not no not third Existing or future devices developed by the Company may may may Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and do not not 2019 2018 Balance, beginning of year $ 260 $ 146 Provision (56 ) 120 Recoveries/write-offs (185 ) (6 ) Balance, end of year $ 19 $ 260 Inventories Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first first may Property and Equipment Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets of generally three five Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not not December 31, 2019. Revenue Recognition The Company’s revenues are derived from ( 1 2 3 1. Lightbox sales: The Company sells its products directly to hospitals and medical centers. Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form by the customer acknowledging that the training and installation process is complete. 2. Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured. 3. Service revenue: Service contract revenue is recognized ratably over the term of the service period and maintenance contract revenue is recognized as work is performed. To date, service revenue has been insignificant. The Company offers its customers the ability to purchase or lease its Lightbox. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow certain strategic accounts to install and utilize the Lightbox for a limited trial period of three six The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases No. 2014 09, Revenue from Contracts with Customers (Topic 606 The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not not For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not not The Company estimates reductions in revenue for potential returns of products by customers. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of its products. The Company expenses shipping and handling costs as incurred and includes them in the cost of revenues. When the Company bills shipping and handling costs to customers, such amounts billed are included as a component of revenue. Cost of Revenues Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs. Product Warranty Costs The Company typically offers a one 201 9 201 8 Balance, beginning of year $ 272 $ 390 Warranty provision 71 333 Usage/Release (128 ) (451 ) Balance, end of year $ 215 $ 272 Research and Development The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with pre-clinical and clinical development activities, and costs for prototype products that are manufactured prior to market approval for that prototype product; internal and external costs associated with the Company’s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility and related expenses. Clinical Trials The Company accrues and expenses costs for its clinical trial activities performed by third Stock-Based Compensation Stock-based compensation for the Company includes amortization related to all stock options, restricted stock units (“RSU”), based on the grant-date estimated fair value. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the vesting period of the award. The Company measures the fair value of RSUs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. As allowed under ASU No. 2016‑09, Compensation-Stock Compensation (Topic 718 Foreign Currency The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange losses in other income (expense), net. During the years ended December 31, 2019 2018, $11,000 13,000 Income Taxes The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense when they occur. During the years ended December 31, 2019 2018, not Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholder by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of December 31, 2019 2018, no Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data): Year Ended December 31, 201 9 201 8 Net loss attributable to common stockholders $ (23,030 ) $ (35,692 ) Weighted average common stock outstanding 7,239 1,068 Net loss per share attributable to common stockholders, basic and diluted $ (3.18 ) $ (33.42 ) The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an antidilutive impact due to losses reported: Year Ended December 31, 201 9 201 8 Common stock options 7,549 7,179 Convertible preferred stock 45,015 41,398 Unvested restricted stock units 471,252 92,245 Common stock warrant equivalents 3,197,208 2,077,871 3,721,024 2,218,693 Comprehensive Loss For the years ended December 31, 2019 2018, no Segment and Geographical Information The Company operates and manages its business as one December 31, 2019 2018, 93% 94%, Recent Accounting Pronouncements Adopted: In May 2014, No. 2014 09 , Revenue from Contracts with Customers (Topic 606 605, Revenue Recognition August 2015, No. 2015 14, Revenue from Contracts with Customers (Topic 606 one December 15, 2017. In March 2016, No. 2016 08, Revenue from Contracts with Customers (Topic 606 ) In April 2016, No. 2016 10, Revenue from Contracts with Customers (Topic 606 ) Identifying Performance Obligations and Licensing In May 2016, No. 2016 12, Revenue from Contracts with Customers (Topic 606 ) Narrow-Scope Improvements and Practical Expedients The Company adopted ASC 606 January 1, 2018, not In May 2017, No. 2017 09, Compensation - Stock Compensation (Topic 718 ) 718. January 1, 2018 not In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 ): Classification of Certain Cash Receipts and Cash Payments December 15, 2017, January 1, 2018 not In February 2016, No. 2016 02, Leases (Topic 842 ). 842 one July, 842 No. 2018 10, Codification Improvements to Topic 842, Leases No. 2018 11, Leases (Topic 842 ): Targeted Improvements January 1, 2019 $1.8 no $962,000 December 31, 2018 In June 2018, No. 2018 07, Compensation - Stock Compensation (Topic 718 ): Improvements to Nonemployee Share-Based Payment Accounting, 718 718 not 1 2 606. December 15, 2018, no 606. July 1, 2018 not

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three Level 1—Quoted Level 2—Inputs 1 not Level 3—Unobservable no As of December 31, 2019 2018, 1 December 31, 2019 2018, no 2. December 31, 2018, 3, 9 no December 31, 2019 2018.

Note 4 - Inventories

Note 4 - Inventories	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventories consisted of the following (in thousands): December 31, 201 9 201 8 Raw materials $ 1,426 $ 1,162 Work-in-process 596 158 Finished products 1,890 2,102 Total inventories $ 3,912 $ 3,422

Note 5 - Property and Equipment

Note 5 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment, net, consisted of the following (in thousands): December 31, 201 9 201 8 Computer software $ 122 $ 124 Computer equipment 144 197 Machinery and equipment 1,878 1,784 Furniture and fixture 78 78 Leasehold improvements 311 326 Equipment held by customers 3,076 2,718 5,609 5,227 Less: Accumulated depreciation and amortization (3,948 ) (3,155 ) Add: Construction-in-progress — 6 $ 1,661 $ 2,078 Depreciation expense for the years ended December 31, 2019 2018, $890,000 $934,000, not $586,000 $499,000 December 31, 2019 2018, $1.2 $1.4 December 31, 2019 2018,

Note 6 - Accrued Expenses and O

Note 6 - Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	6. Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 201 9 201 8 Accrued sales tax $ 18 $ 435 Accrued professional fees 30 41 Accrued travel expenses 89 74 Accrued product warranty costs 214 272 Accrued clinical trial costs 101 111 Accrued restructuring charge — 98 Other accrued liabilities 202 418 $ 654 $ 1,449

Note 7 - Borrowings

Note 7 - Borrowings	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	7. CRG On September 22, 2015, $50 March 29, 2017. $30 September 22, 2015. $10 June 15, 2016 On February 14, 2018, $38 $3.8 March 2, 2020, Under the Loan Agreement, as amended, no third 2021. not 12.5%. third 2021, $1.4 $2.7 2021, $5.5 2022 $2.7 2023. The Company may 5.0% 1.0% no seven 1.5% 15.0% The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for pre-specified liquidity and revenue requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the original Loan Agreement included a covenant that the Company maintain a minimum of $5 2.0 may On February 14, 2018, No. 2 ● extend the interest only payment period and the period during which the Company may June 30, 2021; ● provide for a 15% ● permit the Company to make the entire interest payment for payment dates in 2018 2019 no ● extend the maturity date to June 30, 2023; ● modify certain of the covenants, including the indebtedness covenant, lien covenant and restricted payments covenant, to eliminate or modify permitted exceptions to the restrictions in those covenants; ● modify the financial covenants to reduce the minimum liquidity requirement to $3.5 2018 2019, $15 2020, $20 2021 $25 2022; ● provide CRG with board observer rights. On March 2, 2020, No. 3 ● Extend the period that the Company can make interest payments in payment in kind (PIK) to June 30, 2020; ● Lower the Minimum Revenue Covenants to $10 2020, $12 2021, $15 2022; ● Insert certain terms to clarify that all fees, including the prepayment premium, are due if the obligations are accelerated; and ● Insert a new provision to make clear that to the extent the Company divides its assets/liabilities into divisions, such assets/liabilities will be treated as transferred to a third As of December 31, 2019, As of December 31, 2019, Year Ending December 31, 2020 $ — 2021 3,400 2022 6,266 2023 4,518 14,184 Less: Amount of PIK additions and facility fee to be accreted subsequent to December 31, 2019 (4,629 ) Less: Amount representing debt financing costs (588 ) Borrowings, as of December 31, 2019 $ 8,967 In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 December 31, 2019 2018, $588,000 $757,000, $169,000 $117,000 December 31, 2019 2018, $1.5 $5.4 December 31, 2019 2018, Due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG, the entire amount of borrowings at December 31, 2019 2018 not

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Lease Commitments The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease that originally were to expire in November 2019. $369,000 On October 19, 2017, one December 1, 2017 November 15, 2019 15 $82,410 Upon the adoption of Topic 842 January 1, 2019, $1.8 Additionally, as a result of the adoption of Topic 842, $1.1 December 31, 2019. $962,000 December 31, 2018 On April 1, 2019, five November 30, 2019. November 30, 2024. $5.8 November 2024, December 1, 2019. not In connection with the amendment the Company adjusted its right-of-use asset and lease liability to $6.0 6.5% For the year ended December 31, 2019, $1.4 December 31, 2018 $2.0 December 31, 2019 $676,000. $461,000 December 31, 2019. The following table presents the future operating lease payments and lease liability included on the balance sheet related to the Company’s operating lease as of December 31, 2019 ( Year Ending December 31, 2020 $ 1,085 2021 1,123 2022 1,162 2023 1,203 2024 1,138 5,711 Less: Imputed interest (854 ) Leasehold liability as of December 31, 2019 $ 4,857 Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may may not not The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may may not Legal Proceedings Except as set forth below, we are not may Between May 22, 2017 May 25, 2017, three January 2015 No. 17 02240, No. 17 02284, No. 17 02307. 1933. June 12, 2017, On June 22, 2017, June 23, 2017, July 21, 2017, August 9, 2017, No. 17 02284, September 22, 2017, October 31, 2017, June 20, 2018, On October 11, 2017, November 21, 2017, January 26, 2018. March 19, 2018, January 30, 2015, April 10, 2017. The Company and its directors believe that the foregoing lawsuits were without merit; however, in the interest of avoiding the cost and disruption of continuing to defend against these lawsuits, the Company entered into a settlement of the actions. The settlement is for a total of $5 $1.76 March 2018. October 24, 2018,

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . Stockholders’ Equity Convertible Preferred Stock As of December 31, 2019, 5,000,000 $0.001 48,503 Series A Convertible Preferred Stock On February 14, 2018, $38.0 $3.8 $41.8 2,090,000 8%, no January 2019 December 2019, 2,945 3,580 December 31, 2019. December 31, 2019, 48,325 $3.6 $2.9 December 31, 2019 2018, Series B Convertible Preferred Stock On February 16, 2018, 17,979 $15.5 $0.001 no no not December 31, 2019, 1,523 380,750 178 The Company evaluated the Series B convertible preferred stock issuance in accordance with the provisions of ASC 815, Derivatives and Hedging, may $5.2 February 16, 2018. Series C Convertible Preferred Stock On November 1, 2018, 728,500 8,586 $10.2 $0.001 no December 31, 2018, 2,170 December 31, 2019, 2,170 542,500 no C ommon Stock At December 31, 2019, 100,000,000 $0.001 10,364,663 Common Stock Warrants In connection with the issuance of the Company’s Series E convertible preferred stock in September 2014 January 2015, 50% September 2, 2019. On February 16, 2018, two 1,797,900 one one $4.00 seventh 50 one seventh 60th 50 60 seven April 2019, 60 60 2 seventh December 31, 2019, 1,768,850 On July 13, 2018, 216,618 108,309 $15.80 one one third December 31, 2019, On November 1, 2018, 728,500 8,586 2,875,000 one one $4.00 5 th one 250 December 31, 2018, 2,875,000 ten December 31, 2019, 1,998,079 $8.0 December 31, 2019, 876,840 The Company accounted for the common stock warrants issued during the year ended December 31, 2018 July 2018 November 2018 not February 2018 Expected term (years) 7 Expected volatility 55 % Risk-free interest rate 2 % Dividend rate — As of December 31, 2019 2018, 2,753,999 4,757,539 Stock Plans In January 2015, 2015 “2015 2015 2009 “2009 2015 3,300 2015 2015 not 2009 2009 2015 first 2016, 4,225 5.0% 2018, 300,000 2015 June 8, 2018. June 19, 2019, 800,000 2015 December 31, 2019, 96,896 2015 Pursuant to the Plans, ISOs and NSOs may not 100% 10% not 110% four ten Stock option activity under the Plans is set forth below: Number of Weighted Average Price Weighted Average Remaining Contractual Life (in years) Intri n sic Value Balance at December 31, 2017 7,663 $ 2,917.30 $ — Options granted 3,100 $ 16.70 Options expired (2,550 ) $ 2,725.80 Options forfeited (259 ) $ 3,493.70 Balance at December 31, 2018 7,954 $ 1,707.30 $ — Options expired (448 ) $ 3,061.09 Options forfeited (105 ) $ 1,929.52 Balance at December 31, 2019 7,401 $ 1,309.47 6.81 $ — Exercisable at December 31, 2019 7,224 $ 1,310.25 6.80 $ — Vested and expected to vest at December 31, 2019 7,401 $ 1,309.47 6.81 $ — Additional information related to the status of options as of December 31, 2019 Options Outstanding Options Vested Weighted Weighted Weighted Average Average Average Exercise Options Remaining Exercise Number Exercise Price Outstanding Contractual Life Price Exercisable Price $ 16.70 3,100 8.44 $ 16.70 3,100 $ 16.70 $ 204.00 5 7.56 $ 204.00 3 $ 204.00 $ 820.00 1,001 7.21 $ 820.00 856 $ 820.00 $ 1,052.00 46 7.18 $ 1,052.00 36 $ 1,052.00 $ 1,420.00 70 6.84 $ 1,420.00 70 $ 1,420.00 $ 1,472.00 10 6.83 $ 1,472.00 8 $ 1,472.00 $ 1,800.00 2,440 5.00 $ 1,800.00 2,440 $ 1,800.00 $ 1,980.00 28 0.32 $ 1,980.00 28 $ 1,980.00 $ 4,364.00 10 5.18 $ 1,980.00 10 $ 1,980.00 $ 4,404.00 25 6.43 $ 4,404.00 25 $ 4,404.00 $ 4,952.00 18 6.33 $ 4,952.00 18 $ 4,952.00 $ 5,040.00 24 1.47 $ 5,040.00 24 $ 5,040.00 $ 5,184.00 151 6.19 $ 5,184.00 141 $ 5,184.00 $ 5,196.00 241 6.18 $ 5,196.00 233 $ 5,196.00 $ 5,940.00 14 2.02 $ 5,940.00 14 $ 5,940.00 $ 6,084.00 11 5.58 $ 6,084.00 11 $ 6,084.00 $ 7,290.00 3 4.04 $ 7,290.00 3 $ 7,290.00 $ 7,844.00 110 5.91 $ 7,844.00 110 $ 7,844.00 $ 8,100.00 94 3.73 $ 8,100.00 94 $ 8,100.00 7,401 6.81 $ 1,309.47 7,224 $ 1,310.25 There were no December 31, 2019. December 31, 2019, $72,000 1.0 not December 31, 2019 2018. The Company’s RSUs generally vest annually over three four Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Awards outstanding at December 31, 2017 509 $ 2,377.80 2.87 Awarded 297,753 $ 15.00 Released (128 ) $ 2,739.70 Forfeited (4,068 ) $ 59.70 Awards outstanding at December 31, 2018 294,066 $ 17.34 3.09 Awarded 764,151 $ 1.24 Released (101,575 ) $ 17.95 Forfeited (48,138 ) $ 10.57 Awards outstanding at December 31, 2019 908,504 $ 4.09 1.81 As of December 31, 2019, $3.0 1.8 908,504 $1.0 $1.14 December 31, 2019, December 31, 2019 2018, $116,000 $1,500, 2018 On August 22, 2018, may may not 20,000 August 28, 2019, 40,000 December 31, 2019 36,087 December 31, 2019, 20,204

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	1 0 . Stock-Based Compensation Total noncash stock-based compensation expense relating to the Company’s stock options and RSUs recognized, before taxes, during the years ended December 31, 2019 2018, Year Ended December 31, 201 9 201 8 Cost of revenues $ 169 $ 97 Research and development expenses 535 547 Selling, general and administrative expenses 1,387 2,436 $ 2,091 $ 3,080

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 1 . Income Taxes For the years ended December 31, 2019 2018, zero Year Ended December 31, 201 9 201 8 Tax at federal statutory rate $ (4,084 ) $ (5,787 ) State taxes, net of federal benefit (1,022 ) (1,023 ) Permanent differences 97 228 Change in valuation allowance 5,205 6,582 Research credits (192 ) — Other (4 ) — Provision for taxes $ — $ — Significant components of the Company’s net deferred tax assets as of December 31, 2019 2018 As of December 31, 201 9 201 8 Deferred tax assets: Federal, state and foreign net operating losses $ 75,863 $ 70,286 Research and other credits 4,361 3,655 Operating lease liability 1,237 — Accruals and other 2,847 4,317 Total deferred tax assets 84,308 78,258 Less: Valuation allowance (82,755 ) (78,082 ) Total net deferred tax assets 1,553 176 Deferred liabilities: Fixed assets (198 ) (176 ) Operating lease right of use asset (1,355 ) — Total deferred tax liabilities (1,553 ) (176 ) Net deferred tax assets (liabilities) $ — $ — The valuation allowance increased by $4.7 $7.6 December 31, 2019 2018, In connection with the adoption of ASC 842 March 31, 2019, $1.4 $1.2 December 31, 2019. $6,000, December 31, 2018. As of December 31, 2019, $301.0 $216.1 not 2027 2019, $43.5 December 31, 2017 no As of December 31, 2019, $3.4 $3.6 2027, not may The Company's ability to utilize the net operating loss and tax credit carryforwards in the future may 382 The Company evaluates tax positions for recognition using a more-likely-than- not 50% A reconciliation of the beginning and ending amount of the gross recognized tax benefit is as follows (in thousands): As of December 31, 201 9 201 8 Balance at beginning of year $ 1,760 $ 1,747 Increase based on the tax positions in the current year 177 29 Decrease for tax positions of prior year 157 (16 ) Balance at end of year $ 2,094 $ 1,760 As of December 31, 2019, not The Company does not twelve The Company's policy is to include interest and penalties related to unrecognized tax benefits within its provision for income taxes. Due to the Company's net operating loss position, the Company has not December 31, 2019 2018.

Note 12 - Related-party Transac

Note 12 - Related-party Transactions	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	1 2 . Related-Party Transactions In October 2015, October 2017. December 31, 2019 2018, $80,000 $84,000, December 31, 2019 2018, $27,000 $12,000,

Note 13 - 401(k) Plan

Note 13 - 401(k) Plan	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	1 3 . 401 The Company has a qualified retirement plan under section 401 may 90% may 401 may four no 401

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	1 4 . Subsequent Events On January 31, 2020, 6,428,572 $0.70 $3.7 February 2018 $0.70 On March 2, 2020, No. 3 September 22, 2015, ● Extend the period that the Company can make interest payments in payment in kind (PIK) to June 30, 2020; ● Lower the Minimum Revenue Covenants to $10 2020, $12 2021, $15 2022; ● Insert certain terms to clarify that all fees, including the prepayment premium, are due if the obligations are accelerated; and ● Insert a new provision to make clear that to the extent the Company divides its assets/liabilities into divisions, such assets/liabilities will be treated as transferred to a third The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is included as Exhibit 10.41 10 March 5, 2020,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC (“SEC”). On January 30, 2018, 1 40 June 19, 2019 , 1 - 10 June 21, 2019. not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may may
Fair Value Measurement, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company has evaluated the estimated fair value of its financial instruments as of December 31, 2019 2018.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2019 2018, no December 31, 2019 2018.
Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block]	Concentration of Credit Risk, and Other Risks and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2019 2018. The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. At December 31, 2019 2018, no 10% December 31, 2019 2018, no 10% The Company manufactures its commercial products in-house, including Pantheris and the Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations. The Company is subject to certain risks, including that its devices may not no not third Existing or future devices developed by the Company may may may
Receivable [Policy Text Block]	Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and do not not 2019 2018 Balance, beginning of year $ 260 $ 146 Provision (56 ) 120 Recoveries/write-offs (185 ) (6 ) Balance, end of year $ 19 $ 260
Inventory, Policy [Policy Text Block]	Inventories Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first first may
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets of generally three five
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not not December 31, 2019.
Revenue [Policy Text Block]	Revenue Recognition The Company’s revenues are derived from ( 1 2 3 1. Lightbox sales: The Company sells its products directly to hospitals and medical centers. Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form by the customer acknowledging that the training and installation process is complete. 2. Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured. 3. Service revenue: Service contract revenue is recognized ratably over the term of the service period and maintenance contract revenue is recognized as work is performed. To date, service revenue has been insignificant. The Company offers its customers the ability to purchase or lease its Lightbox. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow certain strategic accounts to install and utilize the Lightbox for a limited trial period of three six The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases No. 2014 09, Revenue from Contracts with Customers (Topic 606 The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not not For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not not The Company estimates reductions in revenue for potential returns of products by customers. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of its products. The Company expenses shipping and handling costs as incurred and includes them in the cost of revenues. When the Company bills shipping and handling costs to customers, such amounts billed are included as a component of revenue.
Cost of Goods and Service [Policy Text Block]	Cost of Revenues Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty Costs The Company typically offers a one 201 9 201 8 Balance, beginning of year $ 272 $ 390 Warranty provision 71 333 Usage/Release (128 ) (451 ) Balance, end of year $ 215 $ 272
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with pre-clinical and clinical development activities, and costs for prototype products that are manufactured prior to market approval for that prototype product; internal and external costs associated with the Company’s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility and related expenses.
Clinical Trials [Policy Text Block]	Clinical Trials The Company accrues and expenses costs for its clinical trial activities performed by third
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Stock-based compensation for the Company includes amortization related to all stock options, restricted stock units (“RSU”), based on the grant-date estimated fair value. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the vesting period of the award. The Company measures the fair value of RSUs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. As allowed under ASU No. 2016‑09, Compensation-Stock Compensation (Topic 718
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange losses in other income (expense), net. During the years ended December 31, 2019 2018, $11,000 13,000
Income Tax, Policy [Policy Text Block]	Income Taxes The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense when they occur. During the years ended December 31, 2019 2018, not
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholder by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of December 31, 2019 2018, no Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data): Year Ended December 31, 201 9 201 8 Net loss attributable to common stockholders $ (23,030 ) $ (35,692 ) Weighted average common stock outstanding 7,239 1,068 Net loss per share attributable to common stockholders, basic and diluted $ (3.18 ) $ (33.42 ) The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an antidilutive impact due to losses reported: Year Ended December 31, 201 9 201 8 Common stock options 7,549 7,179 Convertible preferred stock 45,015 41,398 Unvested restricted stock units 471,252 92,245 Common stock warrant equivalents 3,197,208 2,077,871 3,721,024 2,218,693
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss For the years ended December 31, 2019 2018, no
Segment Reporting, Policy [Policy Text Block]	Segment and Geographical Information The Company operates and manages its business as one December 31, 2019 2018, 93% 94%,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Adopted: In May 2014, No. 2014 09 , Revenue from Contracts with Customers (Topic 606 605, Revenue Recognition August 2015, No. 2015 14, Revenue from Contracts with Customers (Topic 606 one December 15, 2017. In March 2016, No. 2016 08, Revenue from Contracts with Customers (Topic 606 ) In April 2016, No. 2016 10, Revenue from Contracts with Customers (Topic 606 ) Identifying Performance Obligations and Licensing In May 2016, No. 2016 12, Revenue from Contracts with Customers (Topic 606 ) Narrow-Scope Improvements and Practical Expedients The Company adopted ASC 606 January 1, 2018, not In May 2017, No. 2017 09, Compensation - Stock Compensation (Topic 718 ) 718. January 1, 2018 not In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 ): Classification of Certain Cash Receipts and Cash Payments December 15, 2017, January 1, 2018 not In February 2016, No. 2016 02, Leases (Topic 842 ). 842 one July, 842 No. 2018 10, Codification Improvements to Topic 842, Leases No. 2018 11, Leases (Topic 842 ): Targeted Improvements January 1, 2019 $1.8 no $962,000 December 31, 2018 In June 2018, No. 2018 07, Compensation - Stock Compensation (Topic 718 ): Improvements to Nonemployee Share-Based Payment Accounting, 718 718 not 1 2 606. December 15, 2018, no 606. July 1, 2018 not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	2019 2018 Balance, beginning of year $ 260 $ 146 Provision (56 ) 120 Recoveries/write-offs (185 ) (6 ) Balance, end of year $ 19 $ 260
Schedule of Product Warranty Liability [Table Text Block]	201 9 201 8 Balance, beginning of year $ 272 $ 390 Warranty provision 71 333 Usage/Release (128 ) (451 ) Balance, end of year $ 215 $ 272
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 201 9 201 8 Net loss attributable to common stockholders $ (23,030 ) $ (35,692 ) Weighted average common stock outstanding 7,239 1,068 Net loss per share attributable to common stockholders, basic and diluted $ (3.18 ) $ (33.42 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 201 9 201 8 Common stock options 7,549 7,179 Convertible preferred stock 45,015 41,398 Unvested restricted stock units 471,252 92,245 Common stock warrant equivalents 3,197,208 2,077,871 3,721,024 2,218,693

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, 201 9 201 8 Raw materials $ 1,426 $ 1,162 Work-in-process 596 158 Finished products 1,890 2,102 Total inventories $ 3,912 $ 3,422

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 201 9 201 8 Computer software $ 122 $ 124 Computer equipment 144 197 Machinery and equipment 1,878 1,784 Furniture and fixture 78 78 Leasehold improvements 311 326 Equipment held by customers 3,076 2,718 5,609 5,227 Less: Accumulated depreciation and amortization (3,948 ) (3,155 ) Add: Construction-in-progress — 6 $ 1,661 $ 2,078

Note 6 - Accrued Expenses and_2

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 201 9 201 8 Accrued sales tax $ 18 $ 435 Accrued professional fees 30 41 Accrued travel expenses 89 74 Accrued product warranty costs 214 272 Accrued clinical trial costs 101 111 Accrued restructuring charge — 98 Other accrued liabilities 202 418 $ 654 $ 1,449

Note 7 - Borrowings (Tables)

Note 7 - Borrowings (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2020 $ — 2021 3,400 2022 6,266 2023 4,518 14,184 Less: Amount of PIK additions and facility fee to be accreted subsequent to December 31, 2019 (4,629 ) Less: Amount representing debt financing costs (588 ) Borrowings, as of December 31, 2019 $ 8,967

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2020 $ 1,085 2021 1,123 2022 1,162 2023 1,203 2024 1,138 5,711 Less: Imputed interest (854 ) Leasehold liability as of December 31, 2019 $ 4,857

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Expected term (years) 7 Expected volatility 55 % Risk-free interest rate 2 % Dividend rate —
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted Average Price Weighted Average Remaining Contractual Life (in years) Intri n sic Value Balance at December 31, 2017 7,663 $ 2,917.30 $ — Options granted 3,100 $ 16.70 Options expired (2,550 ) $ 2,725.80 Options forfeited (259 ) $ 3,493.70 Balance at December 31, 2018 7,954 $ 1,707.30 $ — Options expired (448 ) $ 3,061.09 Options forfeited (105 ) $ 1,929.52 Balance at December 31, 2019 7,401 $ 1,309.47 6.81 $ — Exercisable at December 31, 2019 7,224 $ 1,310.25 6.80 $ — Vested and expected to vest at December 31, 2019 7,401 $ 1,309.47 6.81 $ —
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Vested Weighted Weighted Weighted Average Average Average Exercise Options Remaining Exercise Number Exercise Price Outstanding Contractual Life Price Exercisable Price $ 16.70 3,100 8.44 $ 16.70 3,100 $ 16.70 $ 204.00 5 7.56 $ 204.00 3 $ 204.00 $ 820.00 1,001 7.21 $ 820.00 856 $ 820.00 $ 1,052.00 46 7.18 $ 1,052.00 36 $ 1,052.00 $ 1,420.00 70 6.84 $ 1,420.00 70 $ 1,420.00 $ 1,472.00 10 6.83 $ 1,472.00 8 $ 1,472.00 $ 1,800.00 2,440 5.00 $ 1,800.00 2,440 $ 1,800.00 $ 1,980.00 28 0.32 $ 1,980.00 28 $ 1,980.00 $ 4,364.00 10 5.18 $ 1,980.00 10 $ 1,980.00 $ 4,404.00 25 6.43 $ 4,404.00 25 $ 4,404.00 $ 4,952.00 18 6.33 $ 4,952.00 18 $ 4,952.00 $ 5,040.00 24 1.47 $ 5,040.00 24 $ 5,040.00 $ 5,184.00 151 6.19 $ 5,184.00 141 $ 5,184.00 $ 5,196.00 241 6.18 $ 5,196.00 233 $ 5,196.00 $ 5,940.00 14 2.02 $ 5,940.00 14 $ 5,940.00 $ 6,084.00 11 5.58 $ 6,084.00 11 $ 6,084.00 $ 7,290.00 3 4.04 $ 7,290.00 3 $ 7,290.00 $ 7,844.00 110 5.91 $ 7,844.00 110 $ 7,844.00 $ 8,100.00 94 3.73 $ 8,100.00 94 $ 8,100.00 7,401 6.81 $ 1,309.47 7,224 $ 1,310.25
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Number of Shares Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term Awards outstanding at December 31, 2017 509 $ 2,377.80 2.87 Awarded 297,753 $ 15.00 Released (128 ) $ 2,739.70 Forfeited (4,068 ) $ 59.70 Awards outstanding at December 31, 2018 294,066 $ 17.34 3.09 Awarded 764,151 $ 1.24 Released (101,575 ) $ 17.95 Forfeited (48,138 ) $ 10.57 Awards outstanding at December 31, 2019 908,504 $ 4.09 1.81

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 201 9 201 8 Cost of revenues $ 169 $ 97 Research and development expenses 535 547 Selling, general and administrative expenses 1,387 2,436 $ 2,091 $ 3,080

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 201 9 201 8 Tax at federal statutory rate $ (4,084 ) $ (5,787 ) State taxes, net of federal benefit (1,022 ) (1,023 ) Permanent differences 97 228 Change in valuation allowance 5,205 6,582 Research credits (192 ) — Other (4 ) — Provision for taxes $ — $ —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 201 9 201 8 Deferred tax assets: Federal, state and foreign net operating losses $ 75,863 $ 70,286 Research and other credits 4,361 3,655 Operating lease liability 1,237 — Accruals and other 2,847 4,317 Total deferred tax assets 84,308 78,258 Less: Valuation allowance (82,755 ) (78,082 ) Total net deferred tax assets 1,553 176 Deferred liabilities: Fixed assets (198 ) (176 ) Operating lease right of use asset (1,355 ) — Total deferred tax liabilities (1,553 ) (176 ) Net deferred tax assets (liabilities) $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	As of December 31, 201 9 201 8 Balance at beginning of year $ 1,760 $ 1,747 Increase based on the tax positions in the current year 177 29 Decrease for tax positions of prior year 157 (16 ) Balance at end of year $ 2,094 $ 1,760

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - USD ($)	Jan. 31, 2020	Aug. 26, 2019	Nov. 01, 2018	Jul. 16, 2018	Feb. 16, 2018	Feb. 14, 2018	Jan. 31, 2020	May 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jul. 13, 2018	Dec. 31, 2017
Retained Earnings (Accumulated Deficit), Ending Balance									$ (348,335,000)	$ (328,885,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance									10,943,000	16,410,000		$ 5,389,000
Proceeds from Issuance or Sale of Equity, Net					$ 15,500,000
Proceeds from Warrant Exercises								$ 8,000,000	$ 7,993,000	$ 581,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,797,900
Preferred Stock, Par or Stated Value Per Share					$ 0.001				$ 0.001	$ 0.001
Debt Conversion, Original Debt, Amount										$ 42,794,000
Share Price									$ 1.14
CRG [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member]
Debt Conversion, Original Debt, Amount					$ 38,000,000	$ 38,000,000
Debt Conversion, Converted Instrument, Amount					$ 41,800,000	$ 41,800,000
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant One [Member]
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock					1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					50
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date					7 years
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 4
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant Two [Member]
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock					1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					50
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date					7 years
Class of Warrant or Right, Expiration Period Following FDA Clearance					60 days
Series C Preferred Stock [Member]
Proceeds from Issuance or Sale of Equity, Net			$ 10,200,000
Stock Issued During Period, Shares, New Issues			8,586
Preferred Stock, Par or Stated Value Per Share			$ 0.001
Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues					17,979
Preferred Stock, Par or Stated Value Per Share					$ 0.001
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues					41,800
Series A Preferred Stock [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares of Common Stock Issuable on Conversion					2,090,000	2,090,000
January 2020 Public Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity, Net	$ 3,700,000						$ 3,700,000
Stock Issued During Period, Shares, New Issues	6,428,572
Share Price	$ 0.70						$ 0.70
August Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Net		$ 3,800,000
Stock Issued During Period, Shares, New Issues		3,813,559
Share Price		$ 1.18
November Public Offering [Member]
Stock Issued During Period, Shares, New Issues			728,500
November Public Offering [Member] | Common Stock Warrants [Member]
Proceeds from Warrant Exercises									$ 8,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,875,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4
November Public Offering [Member] | Series C Preferred Stock [Member]
Proceeds from Issuance or Sale of Equity, Net			$ 10,200,000
Stock Issued During Period, Shares, New Issues			8,586
Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member]
Proceeds from Issuance or Sale of Equity, Net				$ 3,000,000
Sale of Stock, Consideration Received on Transaction				$ 3,000,000
Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member] | Common Stock Warrants [Member]
Stock Issued During Period, Shares, New Issues				216,618
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				108,309							108,309
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1
Shares Issued, Price Per Share				$ 16.425
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 15.80							$ 15.80

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands	Jun. 19, 2019	Jan. 30, 2018	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Apr. 01, 2019USD ($)	Jan. 01, 2019USD ($)
Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax, Total			$ 0	$ 0
Warranty Period			1 year
Foreign Currency Transaction Gain (Loss), before Tax, Total			$ 11,000	(13,000)
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total			$ 0	$ 0
Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation | shares			0	0
Number of Reportable Segments			1
Operating Lease, Right-of-Use Asset			$ 4,856,000		$ 6,000,000
Other Nonoperating Income (Expense), Total			$ 1,101,000	949,000
Number of Operating Segments			1
Operating Lease, Liability, Total			$ 4,857,000		$ 6,000,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset						$ 1,800,000
Other Nonoperating Income (Expense), Total				$ 962,000
Operating Lease, Liability, Total						$ 1,800,000
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers			0	0
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers			0	0
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | UNITED STATES
Concentration Risk, Percentage			93.00%	94.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10	40

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance, beginning of year	$ 260	$ 146
Provision	(56)	120
Recoveries/write-offs	(185)	(6)
Balance, end of year	$ 19	$ 260

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Product Warranty Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance	$ 272	$ 390
Warranty provision	71	333
Usage/Release	(128)	(451)
Balance	$ 215	$ 272

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net loss attributable to common stockholders	$ (23,030)	$ (35,692)
Weighted average common stock outstanding (in shares)	7,239	1,068
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (3.18)	$ (33.42)

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities (in shares)	3,721,024	2,218,693
Common Stock Options [ member]
Antidilutive Securities (in shares)	7,549	7,179
Preferred Stock [Member]
Antidilutive Securities (in shares)	45,015	41,398
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	471,252	92,245
Common Stock Warrants [Member]
Antidilutive Securities (in shares)	3,197,208	2,077,871

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Details Textual) - Fair Value, Inputs, Level 2 [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets, Fair Value Disclosure	$ 0	$ 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0

Note 4 - Inventories - Schedule

Note 4 - Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Raw materials	$ 1,426	$ 1,162
Work-in-process	596	158
Finished products	1,890	2,102
Total inventories	$ 3,912	$ 3,422

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Total	$ 890,000	$ 934,000
Property, Plant and Equipment, Net, Ending Balance	1,661,000	2,078,000
Assets Leased to Others [Member]
Cost, Depreciation	586,000	499,000
Property, Plant and Equipment, Net, Ending Balance	$ 1,200,000	$ 1,400,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment, Net - Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property and Equipment	$ 5,609,000	$ 5,227,000
Less: Accumulated depreciation and amortization	(3,948,000)	(3,155,000)
Property, Plant and Equipment, Net, Ending Balance	1,661,000	2,078,000
Software Development [Member]
Property and Equipment	122,000	124,000
Computer Equipment [Member]
Property and Equipment	144,000	197,000
Machinery and Equipment [Member]
Property and Equipment	1,878,000	1,784,000
Furniture and Fixtures [Member]
Property and Equipment	78,000	78,000
Leasehold Improvements [Member]
Property and Equipment	311,000	326,000
Assets Leased to Others [Member]
Property and Equipment	3,076,000	2,718,000
Property, Plant and Equipment, Net, Ending Balance	1,200,000	1,400,000
Construction in Progress [Member]
Property and Equipment		$ 6,000

Note 6 - Accrued Expenses and_3

Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued sales tax	$ 18	$ 435
Accrued professional fees	30	41
Accrued travel expenses	89	74
Accrued product warranty costs	214	272
Accrued clinical trial costs	101	111
Accrued restructuring charge		98
Other accrued liabilities	202	418
	$ 654	$ 1,449

Note 7 - Borrowings (Details Te

Note 7 - Borrowings (Details Textual)	Feb. 14, 2018USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2023USD ($)	Dec. 31, 2022USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Mar. 02, 2020USD ($)	Sep. 22, 2015USD ($)
Line of Credit Facility, Maximum Borrowing Capacity								$ 50,000,000
Debt Conversion, Original Debt, Amount						$ 42,794,000
Debt Instrument, Redemption Initial Prepayment Premium Percentage								5.00%
Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage								1.00%
Debt Instrument, Redemption Prepayment Premium Percentage after Fifth Year								0.00%
Debt Instrument, Financing Fee Percentage								1.50%
Debt Instrument, Final Facility Fee Percentage	15.00%							15.00%
Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum	$ 3,500,000							$ 5,000,000
Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall								2
Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months	15,000,000						$ 10,000,000
Debt Instrument, Covenant, Compliance Target Minimum Revenue Second Year	20,000,000						12,000,000
Debt Instrument, Covenant Compliance Target Minimum Revenue Third Year	25,000,000						$ 15,000,000
Interest Expense, Total					1,480,000	5,692,000
CRG [Member] | Loan Agreement [Member]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total					588,000	757,000		$ 1,300,000
Amortization of Debt Discount (Premium)					169,000	117,000
Interest Expense, Total					$ 1,500,000	$ 5,400,000
CRG [Member] | Loan Agreement [Member] | Forecast [Member]
Debt Instrument, Periodic Payment, Principal		$ 1,400,000
Debt Instrument, Periodic Payment, Total		$ 2,700,000	$ 2,700,000	$ 5,500,000
CRG [Member] | Loan Agreement [Member] | Series A Preferred Stock Purchase Agreement with CRG [Member]
Debt Conversion, Original Debt, Amount	38,000,000
Debt Conversion, Fees and Prepayment Premium Amount	$ 3,800,000
Debt Instrument, Interest Rate, Stated Percentage								12.50%
CRG [Member] | Loan Agreement [Member] | First Tranche, Borrowed on September 22, 2015 [Member]
Debt Instrument, Face Amount								$ 30,000,000
CRG [Member] | Loan Agreement [Member] | Second Tranche, Borrowed on June 15, 2016 [Member]
Debt Instrument, Face Amount								$ 10,000,000

Note 7 - Borrowings - Schedule

Note 7 - Borrowings - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Borrowings, as of December 31, 2019	$ 8,967	$ 7,486
CRG [Member] | Loan Agreement [Member]
2020
2021	3,400
2022	6,266
2023	4,518
	14,184
Less: Amount of PIK additions and facility fee to be accreted subsequent to December 31, 2019	(4,629)
Less: Amount representing debt financing costs	(588)
Borrowings, as of December 31, 2019	$ 8,967

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual)	Dec. 01, 2017USD ($)	May 25, 2017	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Apr. 01, 2019USD ($)	Jan. 01, 2019USD ($)
Operating Lease, Right-of-Use Asset				$ 4,856,000		$ 6,000,000
Other Nonoperating Income (Expense), Total				1,101,000	949,000
Lessee, Operating Lease, Term of Contract						5 years
Lessee, Operating Lease, Liability, Payments, Due, Total				5,711,000		$ 5,800,000
Lessee, Operating Lease, Discount Rate						6.50%
Operating Lease, Expense				1,400,000	2,000,000
Operating Lease, Right-of-Use Asset, Amortization				676,000
Prepaid Rent				461,000
Operating Lease, Liability, Total				4,857,000		$ 6,000,000
Class Action Lawsuits Related to IPO [Member] | Pending Litigation [Member]
Loss Contingency, New Claims Filed, Number		3
Loss Contingency Accrual, Payments			$ 1,760,000
Class Action Lawsuits Related to IPO [Member] | Settled Litigation [Member]
Litigation Settlement, Amount Awarded to Other Party from All Defendants					5,000,000
Other Income [Member]
Sublease Income				1,100,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset							$ 1,800,000
Other Nonoperating Income (Expense), Total					$ 962,000
Operating Lease, Liability, Total							$ 1,800,000
Facility Lease [Member]
Incentive from Lessor				$ 369,000
Facility Sublease [Member]
Operating Leases Sublease Expiration Prior to Base Lease	15 days
Operating Leases, Monthly Minimum Sublease Rental Payments Receivable Final	$ 82,410

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Future Operating Lease Payments (Details) - USD ($)	Dec. 31, 2019	Apr. 01, 2019
2020	$ 1,085,000
2021	1,123,000
2022	1,162,000
2023	1,203,000
2024	1,138,000
	5,711,000	$ 5,800,000
Less: Imputed interest	(854,000)
Leasehold liability as of December 31, 2019	$ 4,857,000	$ 6,000,000

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Jun. 19, 2019	Nov. 01, 2018	Jul. 16, 2018	Jul. 13, 2018	Feb. 16, 2018	Feb. 14, 2018	Dec. 31, 2019	Jan. 31, 2019	May 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Aug. 28, 2019	Aug. 22, 2018	Dec. 31, 2017	Jan. 31, 2015
Preferred Stock, Shares Authorized							5,000,000			5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share					$ 0.001		$ 0.001			$ 0.001	$ 0.001
Preferred Stock, Shares Issued, Total							48,503			48,503	45,671
Debt Conversion, Original Debt, Amount											$ 42,794,000
Preferred Stock, Shares Outstanding, Ending Balance							48,503			48,503	45,671
Proceeds from Issuance or Sale of Equity, Net					$ 15,500,000
Preferred Stock Deemed Dividend Arising from Beneficial Conversion Feature											$ 5,216,000
Common Stock, Shares Authorized							100,000,000			100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share							$ 0.001			$ 0.001	$ 0.001
Common Stock, Shares, Issued, Total							10,364,663			10,364,663	3,492,200
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,797,900
Class of Warrant or Right, Outstanding							2,753,999			2,753,999	4,757,539
Proceeds from Warrant Exercises									$ 8,000,000	$ 7,993,000	$ 581,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										0
Share-based Payment Arrangement, Expense, Tax Benefit										$ 0	$ 0
Share Price							$ 1.14			$ 1.14
Common Stock, Shares, Outstanding, Ending Balance							10,364,663			10,364,663	3,492,200
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total							$ 72,000			$ 72,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition										1 year
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total							$ 3,000,000			$ 3,000,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition										1 year 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance							908,504			908,504	294,066			509
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value							$ 1,000,000			$ 1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value										$ 116,000	$ 1,500
Minimum [Member] | Common Stock Options [ member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										100.00%
Minimum [Member] | Common Stock Options [ member] | Stockholder with More than 10% Voting Power [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										110.00%
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										3 years
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										4 years
The 2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized															3,300
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Annual															4,225
Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Reserved for Issuance, Percentage on Shares Outstanding															5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	800,000										300,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							96,896			96,896
Officer and Director Share Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized												40,000	20,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							20,204			20,204
Stock Issued During Period, Shares, Employee Stock Purchase Plans										36,087
Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member]
Proceeds from Issuance or Sale of Equity, Net			$ 3,000,000
November Public Offering [Member]
Stock Issued During Period, Shares, New Issues		728,500
Common Stock Warrants, Issued with Series E Convertible Preferred Stock [Member]
Class of Warrant or Right, Securities Called as Percentage of Convertible Preferred Stock Shares							50.00%			50.00%
Common Stock Warrants, Issued with Series B Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,797,900		1,768,850			1,768,850
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant One [Member]
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock					1
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 4
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date					7 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					50
Common Stock Warrants, Issued with Series B Preferred Stock, Warrant Two [Member]
Class of Warrant or Right, Number of Warrants Issued for Each Share of Preferred Stock					1
Class of Warrant or Right, Contingent Expiration Period Following Initial Exercise Date					7 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right					50
Class of Warrant or Right, Expiration Period Following FDA Clearance					60 days
Common Stock Warrants [Member] | Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member]
Stock Issued During Period, Shares, New Issues			216,618
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			108,309	108,309
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 15.80	$ 15.80
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Common Stock Warrants [Member] | November Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,875,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Outstanding							876,840			876,840
Class of Warrant or Right, Exercised										1,998,079
Proceeds from Warrant Exercises										$ 8,000,000
Preferred Stock Warrants [Member] | November Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		250
Class of Warrant or Right, Outstanding											2,875,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues		728,500
Stock Issued During Period, Shares, Employee Stock Purchase Plans										36,087	4,401
Common Stock [Member] | Placement Agency Sale - Prospectus Supplement of July 12, 2018 [Member]
Stock Issued During Period, Shares, New Issues				216,618
Common Stock [Member] | November Public Offering [Member]
Stock Issued During Period, Shares, New Issues		728,500
Conversion of Series B Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted										1,523
Conversion of Stock, Shares Issued										380,750
Conversion of Series C Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted										2,170
Conversion of Stock, Shares Issued										542,500
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance							48,325			48,325
Dividends, Preferred Stock, Total										$ 3,600,000	$ 2,900,000
Stock Issued During Period, Shares, New Issues					41,800
Series A Preferred Stock [Member] | CRG [Member]
Preferred Stock Dividends, Shares							3,580	2,945
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share					$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance							178			178
Stock Issued During Period, Shares, New Issues					17,979
Preferred Stock Deemed Dividend Arising from Beneficial Conversion Feature					$ 5,200,000
Series B Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance											2,170
Stock Issued During Period, Shares, New Issues		8,586
Proceeds from Issuance or Sale of Equity, Net		$ 10,200,000
Series C Preferred Stock [Member] | November Public Offering [Member]
Stock Issued During Period, Shares, New Issues		8,586
Proceeds from Issuance or Sale of Equity, Net		$ 10,200,000
Series C Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues											728,500
Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] | Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares of Common Stock Issuable on Conversion					2,090,000	2,090,000
Preferred Stock, Dividend Rate, Percentage						8.00%
CRG [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member]
Debt Conversion, Original Debt, Amount					$ 38,000,000	$ 38,000,000
Debt Conversion, Fees and Prepayment Premium Amount						3,800,000
Debt Conversion, Converted Instrument, Amount					$ 41,800,000	$ 41,800,000

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Assumptions Used to Estimate Fair Value (Details)	Feb. 28, 2018
Measurement Input, Expected Term [Member]
Measurement input	7
Measurement Input, Price Volatility [Member]
Measurement input	0.55
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.02
Measurement Input, Expected Dividend Rate [Member]
Measurement input

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Stock Option Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Options (in shares)	7,954	7,663
Options, weighted average exercise price (in dollars per share)	$ 1,707.30	$ 2,917.30
Options granted (in shares)		3,100
Options granted, weighted average exercise price (in dollars per share)		$ 16.70
Options expired (in shares)	(448)	(2,550)
Options expired, weighted average exercise price (in dollars per share)	$ 3,061.09	$ 2,725.80
Options forfeited (in shares)	(105)	(259)
Options forfeited, weighted average exercise price (in dollars per share)	$ 1,929.52	$ 3,493.70
Options (in shares)	7,401	7,954
Options, weighted average exercise price (in dollars per share)	$ 1,309.47	$ 1,707.30
Options, weighted average remaining contractual life (Year)	6 years 295 days
Exercisable (in shares)	7,224
Exercisable, weighted average exercise price (in dollars per share)	$ 1,310.25
Exercisable, weighted average remaining contractual life (Year)	6 years 292 days
Vested and expected to vest (in shares)	7,401
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 1,309.47
Vested and expected to vest, weighted average remaining contractual life (Year)	6 years 295 days

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity - Options Outstanding and Vested (Details)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Options Outstanding (in shares) | shares	7,401
Weighted Average Remaining Contractual Life (Year)	6 years 295 days
Weighted Average Exercise Price (in dollars per share)	$ 1,309.47
Number Exercisable (in shares) | shares	7,224
Weighted Average Exercise Price, options vested (in dollars per share)	$ 1,310.25
Exercise Price Range 1 [Member]
Exercise Price (in dollars per share)	$ 16.70
Options Outstanding (in shares) | shares	3,100
Weighted Average Remaining Contractual Life (Year)	8 years 160 days
Weighted Average Exercise Price (in dollars per share)	$ 16.70
Number Exercisable (in shares) | shares	3,100
Weighted Average Exercise Price, options vested (in dollars per share)	$ 16.70
Exercise Price Range 2 [Member]
Exercise Price (in dollars per share)	$ 204
Options Outstanding (in shares) | shares	5
Weighted Average Remaining Contractual Life (Year)	7 years 204 days
Weighted Average Exercise Price (in dollars per share)	$ 204
Number Exercisable (in shares) | shares	3
Weighted Average Exercise Price, options vested (in dollars per share)	$ 204
Exercise Price Range 3 [Member]
Exercise Price (in dollars per share)	$ 820
Options Outstanding (in shares) | shares	1,001
Weighted Average Remaining Contractual Life (Year)	7 years 76 days
Weighted Average Exercise Price (in dollars per share)	$ 820
Number Exercisable (in shares) | shares	856
Weighted Average Exercise Price, options vested (in dollars per share)	$ 820
Exercise Price Range 4 [Member]
Exercise Price (in dollars per share)	$ 1,052
Options Outstanding (in shares) | shares	46
Weighted Average Remaining Contractual Life (Year)	7 years 65 days
Weighted Average Exercise Price (in dollars per share)	$ 1,052
Number Exercisable (in shares) | shares	36
Weighted Average Exercise Price, options vested (in dollars per share)	$ 1,052
Exercise Price Range 5 [Member]
Exercise Price (in dollars per share)	$ 1,420
Options Outstanding (in shares) | shares	70
Weighted Average Remaining Contractual Life (Year)	6 years 306 days
Weighted Average Exercise Price (in dollars per share)	$ 1,420
Number Exercisable (in shares) | shares	70
Weighted Average Exercise Price, options vested (in dollars per share)	$ 1,420
Exercise Price Range 6 [Member]
Exercise Price (in dollars per share)	$ 1,472
Options Outstanding (in shares) | shares	10
Weighted Average Remaining Contractual Life (Year)	6 years 302 days
Weighted Average Exercise Price (in dollars per share)	$ 1,472
Number Exercisable (in shares) | shares	8
Weighted Average Exercise Price, options vested (in dollars per share)	$ 1,472
Exercise Price Range 7 [Member]
Exercise Price (in dollars per share)	$ 1,800
Options Outstanding (in shares) | shares	2,440
Weighted Average Remaining Contractual Life (Year)	5 years
Weighted Average Exercise Price (in dollars per share)	$ 1,800
Number Exercisable (in shares) | shares	2,440
Weighted Average Exercise Price, options vested (in dollars per share)	$ 1,800
Exercise Price Range 8 [Member]
Exercise Price (in dollars per share)	$ 1,980
Options Outstanding (in shares) | shares	28
Weighted Average Remaining Contractual Life (Year)	116 days
Weighted Average Exercise Price (in dollars per share)	$ 1,980
Number Exercisable (in shares) | shares	28
Weighted Average Exercise Price, options vested (in dollars per share)	$ 1,980
Exercise Price Range 9 [Member]
Exercise Price (in dollars per share)	$ 4,364
Options Outstanding (in shares) | shares	10
Weighted Average Remaining Contractual Life (Year)	5 years 65 days
Weighted Average Exercise Price (in dollars per share)	$ 1,980
Number Exercisable (in shares) | shares	10
Weighted Average Exercise Price, options vested (in dollars per share)	$ 1,980
Exercise Price Range 10 [Member]
Exercise Price (in dollars per share)	$ 4,404
Options Outstanding (in shares) | shares	25
Weighted Average Remaining Contractual Life (Year)	6 years 156 days
Weighted Average Exercise Price (in dollars per share)	$ 4,404
Number Exercisable (in shares) | shares	25
Weighted Average Exercise Price, options vested (in dollars per share)	$ 4,404
Exercise Price Range 11 [Member]
Exercise Price (in dollars per share)	$ 4,952
Options Outstanding (in shares) | shares	18
Weighted Average Remaining Contractual Life (Year)	6 years 120 days
Weighted Average Exercise Price (in dollars per share)	$ 4,952
Number Exercisable (in shares) | shares	18
Weighted Average Exercise Price, options vested (in dollars per share)	$ 4,952
Exercise Price Range 12 [Member]
Exercise Price (in dollars per share)	$ 5,040
Options Outstanding (in shares) | shares	24
Weighted Average Remaining Contractual Life (Year)	1 year 171 days
Weighted Average Exercise Price (in dollars per share)	$ 5,040
Number Exercisable (in shares) | shares	24
Weighted Average Exercise Price, options vested (in dollars per share)	$ 5,040
Exercise Price Range 13 [Member]
Exercise Price (in dollars per share)	$ 5,184
Options Outstanding (in shares) | shares	151
Weighted Average Remaining Contractual Life (Year)	6 years 69 days
Weighted Average Exercise Price (in dollars per share)	$ 5,184
Number Exercisable (in shares) | shares	141
Weighted Average Exercise Price, options vested (in dollars per share)	$ 5,184
Exercise Price Range 14 [Member]
Exercise Price (in dollars per share)	$ 5,196
Options Outstanding (in shares) | shares	241
Weighted Average Remaining Contractual Life (Year)	6 years 65 days
Weighted Average Exercise Price (in dollars per share)	$ 5,196
Number Exercisable (in shares) | shares	233
Weighted Average Exercise Price, options vested (in dollars per share)	$ 5,196
Exercise Price Range 15 [Member]
Exercise Price (in dollars per share)	$ 5,940
Options Outstanding (in shares) | shares	14
Weighted Average Remaining Contractual Life (Year)	2 years 7 days
Weighted Average Exercise Price (in dollars per share)	$ 5,940
Number Exercisable (in shares) | shares	14
Weighted Average Exercise Price, options vested (in dollars per share)	$ 5,940
Exercise Price Range 16 [Member]
Exercise Price (in dollars per share)	$ 6,084
Options Outstanding (in shares) | shares	11
Weighted Average Remaining Contractual Life (Year)	5 years 211 days
Weighted Average Exercise Price (in dollars per share)	$ 6,084
Number Exercisable (in shares) | shares	11
Weighted Average Exercise Price, options vested (in dollars per share)	$ 6,084
Exercise Price Range 17 [Member]
Exercise Price (in dollars per share)	$ 7,290
Options Outstanding (in shares) | shares	3
Weighted Average Remaining Contractual Life (Year)	4 years 14 days
Weighted Average Exercise Price (in dollars per share)	$ 7,290
Number Exercisable (in shares) | shares	3
Weighted Average Exercise Price, options vested (in dollars per share)	$ 7,290
Exercise Price Range 18 [Member]
Exercise Price (in dollars per share)	$ 7,844
Options Outstanding (in shares) | shares	110
Weighted Average Remaining Contractual Life (Year)	5 years 332 days
Weighted Average Exercise Price (in dollars per share)	$ 7,844
Number Exercisable (in shares) | shares	110
Weighted Average Exercise Price, options vested (in dollars per share)	$ 7,844
Exercise Price Range 19 [Member]
Exercise Price (in dollars per share)	$ 8,100
Options Outstanding (in shares) | shares	94
Weighted Average Remaining Contractual Life (Year)	3 years 266 days
Weighted Average Exercise Price (in dollars per share)	$ 8,100
Number Exercisable (in shares) | shares	94
Weighted Average Exercise Price, options vested (in dollars per share)	$ 8,100

Note 9 - Stockholders' Equity_5

Note 9 - Stockholders' Equity - Restricted Stock Units Award Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Awards outstanding, Shares (in shares)	294,066	509
Awards outstanding, Weighted grant date fair value (in dollars per share)	$ 17.34	$ 2,377.80
Awards outstanding, Weighted average remaining contractual term (Year)	1 year 295 days	3 years 32 days	2 years 317 days
Awarded, Shares (in shares)	764,151	297,753
Awarded, Weighted grant date fair value (in dollars per share)	$ 1.24	$ 15
Released, Shares (in shares)	(101,575)	(128)
Released, Weighted grant date fair value (in dollars per share)	$ 17.95	$ 2,739.70
Forfeited, Shares (in shares)	(48,138)	(4,068)
Forfeited, Weighted grant date fair value (in dollars per share)	$ 10.57	$ 59.70
Awards outstanding, Shares (in shares)	908,504	294,066	509
Awards outstanding, Weighted grant date fair value (in dollars per share)	$ 4.09	$ 17.34	$ 2,377.80

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Allocated Share-based Compensation Expense	$ 2,091	$ 3,080
Cost of Sales [Member]
Allocated Share-based Compensation Expense	169	97
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	535	547
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense	$ 1,387	$ 2,436

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Expense (Benefit), Total
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	4,700,000	7,600,000
Deferred Tax Liability, Operating Lease Right of Use Asset	1,355,000
Deferred Tax Assets, Operating Lease Liability	1,237,000
Change in Deferred Tax Asset due to New Accounting Principle in Period of Adoption		(6,000)
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	0
State and Local Jurisdiction [Member]
Income Tax Expense (Benefit), Total		$ 0
Operating Loss Carryforwards, Total	216,100,000
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	3,600,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	301,000,000
Operating Loss Carryforwards, Not Subject to Expiration	43,500,000
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 3,400,000

Note 11 - Income Taxes - Effect

Note 11 - Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Tax at federal statutory rate	$ (4,084)	$ (5,787)
State taxes, net of federal benefit	(1,022)	(1,023)
Permanent differences	97	228
Change in valuation allowance	5,205	6,582
Research credits	(192)
Other	(4)
Provision for taxes

Note 11 - Income Taxes - Deferr

Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Federal, state and foreign net operating losses	$ 75,863	$ 70,286
Research and other credits	4,361	3,655
Operating lease liability	1,237
Accruals and other	2,847	4,317
Total deferred tax assets	84,308	78,258
Less: Valuation allowance	(82,755)	(78,082)
Total net deferred tax assets	1,553	176
Fixed assets	(198)	(176)
Operating lease right of use asset	(1,355)
Total deferred tax liabilities	(1,553)	(176)
Net deferred tax assets (liabilities)

Note 11 - Income Taxes - Reconc

Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance	$ 1,760	$ 1,747
Increase based on the tax positions in the current year	177	29
Increase for tax positions of prior year	157
Decrease for tax positions of prior year		(16)
Balance	$ 2,094	$ 1,760

Note 12 - Related-party Trans_2

Note 12 - Related-party Transactions (Details Textual) - Consensys Imaging Services [Member] - Field Engineers Services [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction, Expenses from Transactions with Related Party	$ 80,000	$ 84,000
Accounts Payable, Related Parties	$ 27,000	$ 12,000

Note 13 - 401(k) Plan (Details

Note 13 - 401(k) Plan (Details Textual) - Pension Plan [Member] - The 401(k) Plan [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	90.00%
Defined Contribution Plan, Employers Contribution Vesting Period	4 years
Defined Contribution Plan, Cost	$ 0

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($)	Jan. 31, 2020	Feb. 16, 2018	Jan. 31, 2020	Mar. 02, 2020	Dec. 31, 2019	Feb. 14, 2018
Share Price					$ 1.14
Proceeds from Issuance or Sale of Equity, Net		$ 15,500,000
Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months				$ 10,000,000		$ 15,000,000
Debt Instrument, Covenant, Compliance Target Minimum Revenue Second Year				12,000,000		20,000,000
Debt Instrument, Covenant Compliance Target Minimum Revenue Third Year				15,000,000		$ 25,000,000
Subsequent Event [Member] | Loan Agreement [Member] | CRG [Member]
Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months				10,000,000
Debt Instrument, Covenant, Compliance Target Minimum Revenue Second Year				12,000,000
Debt Instrument, Covenant Compliance Target Minimum Revenue Third Year				$ 15,000,000
January 2020 Public Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	6,428,572
Share Price	$ 0.70		$ 0.70
Proceeds from Issuance or Sale of Equity, Net	$ 3,700,000		$ 3,700,000